Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03044197 · ClinicalTrials.gov registry record · NA
Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
A NA study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT03044197 is a NA study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 24 participants.
The verdict
NCT03044197, a NA study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa). With multi-parametric magnetic resonance imaging (mpMRI) we now potentially have a way of increasing the detection of detecting clinically significant prostate cancer (csPCa) while decreasing the detection of non-significant PCa.
Interventions
- DEVICE MRI/ultrasound transperineal prostate biopsy
- DEVICE transrectal ultrasound-guided prostate biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-25 |
| Est. Completion | 2018-04-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03044197
The ClinicalTrials.gov registry entry for NCT03044197 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI/ultrasound transperineal prostate biopsy is the first listed.
NCT03044197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03044197 about?
NCT03044197 is a clinical study titled "Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy". Prostate biopsies are currently the gold standard for the diagnosis of prostate cancer. Many biopsies, however, are unnecessary or cannot detect significant prostate cancer (PCa). With multi-parametric magnetic resonance imaging (mpMRI) we now potentially have a way of increasing the detection of de...
What is the current status of trial NCT03044197?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2017-07-25. Estimated completion is 2018-04-12.
What interventions are being tested in trial NCT03044197?
The interventions under investigation include: MRI/ultrasound transperineal prostate biopsy (DEVICE), transrectal ultrasound-guided prostate biopsy (DEVICE).
Who is sponsoring clinical trial NCT03044197?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.